Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Recruiting 19Active not recruiting 8Not yet recruiting 2Completed 2No longer available 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Myasthenia Gravis 1Multiple Myeloma 1

Interventions

Cisplatin 122Carboplatin 121Drug Therapy 118Bevacizumab 105Capecitabine 99Oxaliplatin 97Radiotherapy 95Paclitaxel 88Gemcitabine 88tislelizumab 87Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 65Fluorouracil 62sintilimab 59Injections 57Surgical Procedures, Operative 56Docetaxel 54anlotinib 51130-nm albumin-bound paclitaxel 48Immune Checkpoint Inhibitors 47fludarabine 46Standard of Care 45Pemetrexed 43Blood Specimen Collection 43Biopsy 43venetoclax 41lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × talquetamab × Clear all
NCT07499323 2026-04-08

Talquetamab in Patients With Refractory Generalized Myasthenia Gravis

First Affiliated Hospital of Chongqing Medical University

Phase NA Not yet recruiting
2 enrolled

Myasthenia Gravis

NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting
400 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡